Boardroom Alpha
Meeting calendar
PLSE · Annual meeting · Tuesday, December 9, 2025

Pulse Biosciences Inc

6 nominees · 5 ballot items.

Election of six directors; ratification of Deloitte & Touche LLP as independent registered public accounting firm for 2025; advisory vote on the compensation of Pulse Biosciences, Inc.'s named executive officers; advisory vote on the frequency of future advisory stockholder votes to approve executive compensation; and such other business as may properly come before the Annual Meeting.

Market cap
$2.0B
1Y TSR
+76.1%
Board grade
B-
Record date
Oct 22, 2025
Filing
DEF 14A
Meeting concluded · Dec 9, 2025

Follow how the vote landed and what changed on Pulse Biosciences Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot5

  1. 1

    Election of six directors

    ManagementBoard: FOR

    Elect six nominees to serve on Pulse Biosciences’ Board of Directors for one-year terms expiring at the 2026 annual meeting of stockholders.

  2. 2

    Ratification of independent registered public accounting firm

    ManagementBoard: FOR

    Ratify Deloitte & Touche LLP as Pulse Biosciences’ independent registered public accounting firm for the fiscal year ending December 31, 2025.

  3. 3

    Advisory vote on executive compensation (say-on-pay

    ManagementBoard: FOR

    Approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement for the fiscal year ending December 31, 2024.

  4. 4

    Advisory vote on the frequency of future advisory stockholder votes on executive compensation

    ManagementBoard: FOR

    Vote on how frequently Pulse Biosciences should solicit advisory stockholder approval of executive compensation (every year, every 2 years, or every 3 years).

  5. 5

    Other business

    Management

    Transact such other business as may properly come before the Annual Meeting.

Director elections

Nominees on the ballot6

Not independent
Tenure on this board
1.9 yrs
Also a director at
Edwards Lifesciences Corp (EW)
Independent
Tenure on this board
8.7 yrs
Also a director at
Summit Therapeutics Inc (SMMT)
Independent
Tenure on this board
8.7 yrs
Also a director at
Summit Therapeutics Inc (SMMT)
Ownership

Top institutional holders10

Latest 13F quarter
1BANK OF AMERICA CORP /DE/1.3%866,061$19M
2VANGUARD CAPITAL MANAGEMENT LLC1.2%815,852$18M
3Portolan Capital Management, LLC1.1%733,372$16M
4BlackRock, Inc.1.0%683,017$15M
5BlackRock, Inc.0.7%493,117$11M
6MASSACHUSETTS FINANCIAL SERVICES CO /MA/0.7%462,899$10M
7STATE STREET CORP0.7%456,927$10M
8GEODE CAPITAL MANAGEMENT, LLC0.6%428,167$9M
9BALYASNY ASSET MANAGEMENT L.P.0.4%265,164$6M
10GRIFFIN ASSET MANAGEMENT, INC.0.3%225,177$5M
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the Pulse Biosciences Inc 2025 annual meeting?
Pulse Biosciences Inc (PLSE) holds its 2025 annual shareholder meeting on Tuesday, December 9, 2025.
What is the record date for the Pulse Biosciences Inc 2025 meeting?
The record date for the Pulse Biosciences Inc 2025 meeting is Wednesday, October 22, 2025. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Pulse Biosciences Inc's 2025 meeting?
The board is presenting 6 director nominees at the Pulse Biosciences Inc 2025 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Pulse Biosciences Inc 2025 meeting?
Shareholders will vote on 5 proposals at the Pulse Biosciences Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer